Incyte (INCY) Q1 2026 earnings summary

Executive summary

• Net sales grew 20% year-over-year in Q1 2026 to $1.10 billion, with total revenue at $1.27 billion, up 21%, driven by strong demand across all marketed products and robust performance in hematology, oncology, and immunology segments.

• Jakafi net sales rose 7% to $758 million; Opzelura net sales increased 20% to $143 million; Hematology and Oncology portfolio net sales surged 116% to $204 million.

• The company is transitioning from reliance on a single cornerstone product to a diversified, growth-oriented portfolio, with four anticipated product approvals and launches from mid-2026 to early 2027.

• Multiple late-stage pipeline advancements and regulatory milestones were achieved, including FDA acceptance for povorcitinib in HS, positive Phase 3 data in vitiligo, and 10 Phase 3 studies underway.

• Several executive appointments were made to strengthen leadership and operational execution.

Financial highlights

• Q1 2026 total revenue: $1.27 billion (up 21% year-over-year); net sales: $1.10 billion (up 20%).

• Jakafi sales: $758 million, up 7% year-over-year; Opzelura: $143 million, up 20%; Hematology and Oncology: $204 million, up 116%.

• Core business excluding Jakafi grew 63% year-over-year, led by Opzelura and strong international growth in vitiligo.

• GAAP net income was $303 million, up from $158 million; diluted EPS was $1.47, up from $0.80; operating income rose to $301 million from $205 million.

• R&D expenses were $516 million (up 18%), SG&A expenses were $328 million (up 1%), and cost of sales increased to $104.5 million.

Outlook and guidance

• Full-year 2026 net sales guidance: $4.77–$4.94 billion; Jakafi: $3.22–$3.27 billion; Opzelura: $750–$790 million; Hematology and Oncology: $800–$880 million.

• R&D and SG&A operating expenses projected at $3.50–$3.68 billion (GAAP); non-GAAP at $3.21–$3.38 billion.

• Four anticipated product approvals and launches expected from mid-2026 to early 2027.

• Cost of sales expected to remain stable at ~9% of net sales.

• Jakafi expected to remain a major contributor until patent expiry in 2028.